SPRO Stock Gets Stronger EPS Forecast from HC Wainwright

Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – Analysts at HC Wainwright raised their Q4 2026 EPS estimates for shares of Spero Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($0.58) per share.

A number of other research analysts have also recently commented on the company. Zacks Research raised Spero Therapeutics to a “hold” rating in a research report on Monday, September 14th. Wall Street Zen lowered Spero Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 14th. Cantor Fitzgerald assumed coverage on Spero Therapeutics in a report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price objective for the company. Weiss Ratings upgraded Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, November 10th. Finally, Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.00.

Get Our Latest Report on Spero Therapeutics

Spero Therapeutics Price Performance

NASDAQ:SPRO opened at $0.83 on Wednesday. The business has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.89. Spero Therapeutics has a 1 year low of $0.81 and a 1 year high of $3.08. The company has a market capitalization of $48.14 million, a P/E ratio of 10.93 and a beta of 1.59.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.29). Spero Therapeutics had a net margin of 24.90% and a return on equity of 13.98%.

Insider Buying and Selling

In related news, insider Esther Rajavelu sold 40,851 shares of Spero Therapeutics stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the transaction, the insider directly owned 946,000 shares in the company, valued at approximately $983,840. The trade was a 4.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently made changes to their positions in SPRO. Alphabet Inc. bought a new stake in Spero Therapeutics during the 2nd quarter worth approximately $1,967,000. BlackRock Inc. bought a new position in Spero Therapeutics in the 2nd quarter valued at $1,314,000. GSA Capital Partners LLP bought a new position in Spero Therapeutics in the 2nd quarter valued at $632,000. Marshall Wace LLP bought a new position in Spero Therapeutics in the 3rd quarter valued at $236,000. Finally, Empowered Funds LLC bought a new position in Spero Therapeutics in the 3rd quarter valued at $77,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.

Read More

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.